■ SpyGlass Pharma announced closing $90 million in Series C financing led by RA Capital Management alongside existing investors New Enterprise Associates and Vensana Capital, as well as new investors Samsara BioCapital and Vertex Ventures HC. The cash infusion will enable the company to conduct multiple US clinical trials of its innovative drug delivery platform, a news release stated.
The SpyGlass system seeks to be the world’s first, IOL-mounted, controlled-release drug-delivery platform that can deliver multiple years of therapy when implanted at the time of cataract surgery, according to the company.
“We believe our approach represents a paradigm shift in the treatment of eye diseases, such as glaucoma, with significant advantages compared to currently commercialized therapies,” said Malik Y. Kahook, MD, cofounder and president of SpyGlass Pharma. “The efficacy and safety demonstrated from the first-in-human feasibility trial showing 45% mean IOP lowering in glaucoma patients, with 100% of subjects off all topical medication 9 months after implantation, is remarkable.” GP